Fixed dose combination abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) among HIV-1 and tuberculosis (TB)-coinfected patients was evaluated and outcomes between early vs. delayed initiation were compared. In a randomized, pilot study conducted in the Kilimanjaro Region of Tanzania, HIV-infected inpatients with smear-positive TB and total lymphocyte count <1200/mm3 were randomized to initiate ABC/3TC/ZDV either 2 (early) or 8 (delayed) weeks after commencing antituberculosis therapy and were followed for 104 weeks. Of 94 patients screened, 70 enrolled (41% female, median CD4 count 103 cells/mm3), and 33 in each group completed 104 weeks. Two deaths and 12 serious adverse events (SAEs) were observed in the early arm vs. one death, one clinical failure, and seven SAEs in the delayed arm (p = 0.6012 for time to first grade 3/4 event, SAE, or death). CD4 cell increases were +331 and +328 cells/mm3, respectively. TB-immune reconstitution inflammatory syndromes (TB-IRIS) were not observed in any subject. Using intent-to-treat (ITT), missing = failure analyses, 74% (26/35) vs. 89% (31/35) randomized to early vs. delayed therapy had HIV RNA levels <400 copies/ml at 104 weeks (p = 0.2182) and 66% (23/35) vs. 74% (26/35), respectively, had HIV RNA levels <50 copies/ml (p = 0.6026). In an analysis in which switches from ABC/3TC/ZDV = failure, those receiving early therapy were less likely to be suppressed to <400 copies/ml [60% (21/35) vs. 86% (30/35), p = 0.030]. TB-IRIS was not observed among the 70 coinfected subjects beginning antiretroviral treatment. ABC/3TC/ZDV was well tolerated and resulted in steady immunologic improvement. Rates of virologic suppression were similar between early and delayed treatment strategies with triple nucleoside regimens when substitutions were allowed.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing, 2008. http://www.who.int/tb/publications/global_report/en/. 2009 August 18.
2.
AnsariNA, KombeAH, KenyonTAet al.Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997–1998. Int J Tuberc Lung Dis, 2002; 6:55–63.
3.
CorbettEL, MarstonB, ChurchyardGJ, De CockKM. Tuberculosis in sub-Saharan Africa: Opportunities, challenges, and change in the era of antiretroviral treatment. Lancet, 2006; 367:926–937.
4.
GrantAD, DjomandG, De CockKM. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS, 1997; 11,Suppl B:S43–S54.
5.
Ole-NguyaineS, CrumpJA, KibikiGSet al.HIV-associated morbidity, mortality, and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. Ann Trop Med Parasitol, 2004; 98:171–179.
6.
RanaFS, HawkenMP, MwachariCet al.Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr, 2000; 24:23–29.
7.
BretonG, DuvalX, EstellatCet al.Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis, 2004; 39:1709–1712.
8.
KumarasamyN, ChaguturuS, MayerKHet al.Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr, 2004; 37:1574–1576.
9.
McIlleronH, MeintjesG, BurmanWJ, MaartensG. Complications of antiretroviral therapy in patients with tuberculosis: Drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis, 2007; 196,Suppl 1:S63–S75.
10.
MichailidisC, PozniakAL, MandaliaS, BasnayakeS, NelsonMR, GazzardBG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther, 2005; 10:417–422.
11.
NaritaM, AshkinD, HollenderES, PitchenikAE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med, 1998; 158:157–161.
12.
NavasE, Martin-DavilaP, MorenoLet al.Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med, 2002; 162:97–99.
13.
OlallaJ, PulidoF, RubioRet al.Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease. Int J Tuberc Lung Dis, 2002; 6:71–75.
14.
LawnSD, MyerL, BekkerLG, WoodR. Tuberculosis-associated immune reconstitution disease: Incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS, 2007; 21:335–341.
15.
GulickRM, MellorsJW, HavlirDet al.Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med, 1997; 337:734–739.
16.
HammerSM, SquiresKE, HughesMDet al.A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med, 1997; 337:725–733.
17.
MocroftA, VellaS, BenfieldTLet al.Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet, 1998; 352:1725–1730.
18.
BraitsteinP, BrinkhofMW, DabisFet al.Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet, 2006; 367:817–824.
19.
BreenRA, SmithCJ, BettinsonHet al.Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax, 2004; 59:704–707.
20.
ShelburneSA, VisnegarwalaF, DarcourtJet al.Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS, 2005; 19:399–406.
21.
AckahAN, CoulibalyD, DigbeuHet al.Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet, 1995; 345:607–610.
22.
PerriensJH, St LouisME, MukadiYBet al.Pulmonary tuberculosis in HIV infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med, 1995; 332:779–784.
23.
ChaissonRE, ClermontHC, HoltEAet al.Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med, 1996; 154:1034–1038.
24.
Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis, 2007. http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/PDF/tbhiv.pdf. 2009 August 18.
25.
HarriesAD, MaherD, GrahamS. TB/HIV: A Clinical Manual, 2nd. World Health Organization, 2004.
26.
World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach (2003 Revision), 2004. http://www.who.int/3by5/publications/documents/arv_guidelines/en/index.html. 2009 August 18.
GuptaR, HillA, SawyerAW, PillayD. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: A systematic review of clinical trials. Clin Infect Dis, 2008; 47:712–722.
29.
BoulleA, OrrelC, KaplanRet al.Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther, 2007; 12:753–760.
30.
World Health Organization. Transaction Prices for Antiretroviral Medicines and HIV Diagnostics from 2004 to September, 2008. http://www.who.int/hiv/amds/GPRMsummaryReportOct2008.pdf. 2009 August 18.
31.
Renaud-TheryF, NguimfackBD, VitoriaMet al.Use of antiretroviral therapy in resource-limited countries in 2006: Distribution and uptake of first- and second-line regimens. AIDS, 2007; 21,Suppl 4:S89–S95.
32.
SrikantiahP, WalusimbiMN, KayanjaHKet al.Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS, 2007; 21:1972–1974.
33.
CrumpJ, vanIngen J, MorrisseyAet al.Invasive disease caused by nontuberculous mycobacteria in HIV-infected patients in Tanzania. Emerg Infect Dis, 2009; 15:53–55.
34.
DeanGL, EdwardsSG, IvesNJet al.Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS, 2002; 16:75–83.
35.
DhedaK, LampeFC, JohnsonMA, LipmanMC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis, 2004; 190:1670–1676.
36.
AkksilpS, KarnkawinpongO, WattanaamornkiatWet al.Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis, 2007; 13:1001–1007.
37.
SanguanwongseN, CainKP, SuriyaPet al.Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr, 2008; 48:181–189.
38.
ZolopaA, AndersenJ, KomarowLet al.Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy. PLOS ONE, 2009; 4:e5575.
39.
LawnSD, HarriesAD, AnglaretX, MyerL, WoodR. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS, 2008; 22:1897–1908.
40.
DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS, 2006; 20:1391–1399.
41.
HuttnerAC, KaufmannGR, BattegayM, WeberR, OpravilM. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. AIDS, 2007; 21:939–946.
42.
StaszewskiS, KeiserP, MontanerJet al.Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA, 2001; 285:1155–1163.
43.
BartlettJA, JohnsonJ, HerreraGet al.Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr, 2006; 43:284–292.
44.
YoungB, SquiresK, PatelPet al.First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS, 2008; 22:1673–1675.
